Results 11 to 20 of about 1,653 (153)
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma [PDF]
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for BRAF-mutant melanoma.
Ernesto Rossi +12 more
doaj +3 more sources
Stereotactic body radiotherapy (SBRT) has emerged as a technique to treat oligoprogressive sites among patients with breast cancer who are otherwise doing well on systemic therapy. This study systematically reviewed the efficacy and safety of SBRT in the
Bernie Yan +4 more
doaj +2 more sources
Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study. [PDF]
Aims: To evaluate survival outcomes and toxicology profiles in oligometastatic/oligoprogressive patients treated with SBRT for adrenal metastases. Methods: We retrospectively analyzed 25 metastatic adrenal lesions in 24 oligometastatic/oligoprogressive ...
Giuseppe Facondo +5 more
doaj +2 more sources
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR) [PDF]
Background The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when added to endocrine therapy, had ...
Reem Alomran +9 more
doaj +2 more sources
Introduction: The role of local ablative treatments, including stereotactic body radiotherapy (SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer (SCLC) has a poor prognosis, with common diffuse metastatic evolution.
Antonin Levy +13 more
doaj +2 more sources
Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer [PDF]
Purpose: Oligoprogressive lesions are observed in a subset of patients who progress to castration-resistant prostate cancer (CRPC), while other lesions remain controlled by systemic therapy. This study evaluates the impact of progression-directed therapy
Jun Nyung Lee +12 more
doaj +2 more sources
Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases [PDF]
Tanju Berber,1 Abdullah Sakin2 1Department of Radiation Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey; 2Department of Medical Oncology, Medipol University, Bahçelievler Medipol Hospital, Istanbul, TurkeyCorrespondence: Tanju Berber,
Berber T, Sakin A
doaj +2 more sources
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to progression despite androgen deprivation therapy (ADT).
Rafał B. Drobot +2 more
doaj +2 more sources
We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC.
Riccardo Ray Colciago +10 more
doaj +2 more sources
Oligoprogressive renal cell carcinoma: What is the role of surgery? [PDF]
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Re C +9 more
europepmc +2 more sources

